Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Cyclooxygenase-2 inhibitors and free flap complications after autologous breast reconstruction: A retrospective cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Delayed two-stage breast reconstruction: The impact of radiotherapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A simple method to secure data-driven improvement of perioperative care

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comment on "Epidural Analgesia (TEA) vs. IV-PCA After Open Liver Surgery"

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Enhanced recovery after surgery components and perioperative outcomes: a nationwide observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Fast-track hip and knee arthroplasty in older adults-a prospective cohort of 1,427 procedures in patients ≥85 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: A key component of modern analgesics is the use of multimodal opioid-sparing analgesia (MOSA). In the past, our analgesic regime after autologous breast reconstruction (ABR) included either NSAID or a selective cyclooxygenase-2 (COX-2) inhibitor. COX-2 inhibitors are superior to NSAIDs because of the well-known side effects of NSAID treatment (bleeding/gastrointestinal ulcers). However, COX-2 inhibitors have been suggested to increase flap failure rates. We report our experience in using COX-2 inhibitors as part of our post-operative MOSA after ABR using free flaps.

MATERIALS AND METHODS: A total of 132 unilateral secondary ABR were performed (DIEP or MS-TRAM) in the NSAID period (2007-2011) and 128 in the COX-2 inhibitor period (2006, 2012-2014). The same surgical team operated all patients. Data were collected prospectively and reviewed to compare the two periods, with special focus on reoperations due to bleeding/haematomas and flap thrombosis/failure. Comparisons between the COX-2 inhibitor and NSAID were made.

RESULTS: Median age, ischaemia time, blood loss and operating time were similar in the two periods. Significantly, more patients were re-operated because of post-operative haematoma in the NSAID group (n = 13/132, 9.8%) than in the COX-2 inhibitor group (n = 4/128, 3.1%) (p = 0.02). We found no difference in flap loss rates between the NSAID (n = 2/132, 1.5%) and the COX-2 inhibitor groups (n = 3/128, 2.3%) (p = 0.63). No patients suffered from thromboembolic complications or gastrointestinal bleeding.

CONCLUSIONS: Multimodal analgesia using a COX-2 inhibitor is safe in ABR with free flaps and does not increase flap failure. COX-2 inhibitors seem superior to NSAID with reduced risk of post-operative haematomas.

TidsskriftJournal of plastic, reconstructive & aesthetic surgery : JPRAS
Udgave nummer11
Sider (fra-til)1543-1546
Antal sider4
StatusUdgivet - 20 jun. 2017

ID: 51603628